Company intelligence / Profile preview

Cytopharma

Hammam Zriba, Zaghouan, Tunisiacytopharma.com ↗

Ownership: Private
Employees: ~79
Development stage: Commercial

Overview

Cytopharma is a leading manufacturer of generic cytotoxic oncology drugs in Africa and the Middle East. The company holds EU GMP certification and supplies both public and private sectors with a portfolio exceeding twenty injectable chemotherapy products. It also offers contract development and manufacturing services to third parties.

Therapeutic areas: Oncology
Modalities: Small moleculeInjectable formulation
Industry: Biotech

Drug pipeline

1 asset

amygdalin

Commercial

Indications: Cancer

Partnerships

Open to distribution/co-marketing/CDMO partnerships across Africa/Middle East/Europe

Beyond the preview

Go deeper on Cytopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytopharma.

Explore the full profile